Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
debt to two lenders in the amount of $163,000.00 has been retired.
Nite on the BID @ .0268
When a company is bought out, it no longer exists as its own independently traded company. Investors receive some type of compensation for their existing shares, such as cash or shares of stock in another company.
Tomorrow will be like last Monday. Slow start, then Boom!! New highs.. GLTA
30 new board followers since Friday
Know what you own..
Lots of excitement here this weekend..
Technical Analysis can be pretty reliable. Unfortunately only certain set ups can be trusted with penny stocks.
FDA Regulation of Stem-Cell–Based Therapies
http://www.nejm.org/doi/full/10.1056/NEJMhpr063086
"Our cutting edge technology in autologous stem cell treatment for erectile dysfunction is anticipated to be received by the urologic community with great enthusiasm as our CaverStem TM procedure represents an all-natural alternative for those patients resistant to the use of PDE5 inhibitors such as Viagra and Cialis," said Thomas Ichim PhD, Founder and Chief Scientific Officer of Creative Medical Technology Holdings, Inc.
The company is currently preparing an Investigational New Drug application with the FDA for use of its AmnioStem stem cell product for treatment of radiation toxicity through its neurology focused subsidiary CerebroStem LLC and its Medical Director, Santosh Kesari, MD, Ph.D, FANA, FAAN, Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, as well as Director of Neuro-Oncology, Providence Saint John's Health Center and leads the Pacific Neuroscience Research Center at Pacific Neuroscience Institute.
American Urological Association (AUA) conference on May 18-21, 2018 in San Francisco. Will be exhibiting it's patented CaverStemTM stem cell procedure for erectile dysfunction.
AmnioStem™ cells were superior at suppressing production of inflammatory mediators such as TNF-alpha, interferon gamma, and interleukin-12 as compared to other stem cells.
"Control of molecules such as TNF-alpha represents a multi-billion dollar market.
Monday will be the same as last Monday. Slow start, then Boom!! New highs..
It's the $$ you make from your trade that counts.. Believe in your decisions
So, this little thing can move if pushed. And right now, it’s getting a push. .03's are coming..
Unregistered Sales of Equity Securities.
From April 20, 2018 through April 27, 2018, we issued an aggregate of 13,566,753 shares upon the conversions of outstanding notes and 28,548,513 shares upon the cashless exercise of outstanding warrants. These conversions were made pursuant to the exemption provided by Section 3(a)(9) of the Securities Act of 1933. As a result of these issuances, we have outstanding 641,502,996 shares of common stock as of April 27, 2018.
Thanks for all the info today. Will be in shortly and here for the long hull. SURG has IMO great potential moving forward. GLTA
Have a great weekend everyone. CELZ strong
Another great day. This company is making all the right moves.
New HOD .026 +.0038 (+17.12%)
It's going to pop..Get ready.!!
Cut & Paste and send to Admin.
.0234 +.0012 (+5.41%) Just warming up
What's up with this weeeeeee thing.. Childs play. Many types of investors on this board. Lets keep it in the best interest of all.
This stock could be very profitable in the future.
Stock moves in a positive direction and they disappear.
Don't listen these negative posters. #NotGettingMyShares
Grabbed more @ .0193. Thank you
I've found this doing DD on another stock. Will be taking a starter position today. Thanks
On April 23, 2018, and effective the same date, on the recommendation of the Registrant’s Board of Directors, the Registrant engaged RBSM LLP, as its independent registered audit firm to audit the Registrant’s financial statements for the fiscal year ended December 31, 2018 and to perform procedures related to the financial statements included in the Registrant’s quarterly reports on Form 10-Q, beginning with the quarter ending March 31, 2018.
https://surgephone.com/ $30 monthly.. Unlimited..
8-K Out
Item 4.01 Change In Registrant’s Certifying Accountant
(a) Our previous independent registered public accounting firm:
On April 23, 2018, Fiondella, Milone & LaSaracina LLP (the “Former Auditor”) resigned as independent registered public accounting firm for U.S. Stem Cell, Inc. (the “Company”). Except as set forth below, the reports of the Former Auditor on the Company’s financial statements for years ended December 31, 2017 and December 31, 2016 did not contain an adverse opinion or disclaimer of opinion, and such reports were not qualified or modified as to uncertainty, audit scope or accounting principle. However, the reports of the Former Auditor on the Company’s financial statements for each of the years ended December 31, 2017 and December 31, 2016 contained an explanatory paragraph, which notes that there was substantial doubt about the Company’s ability to continue as a going concern.
During the years ended December 31, 2017 and December 31, 2016, and the subsequent period through April 23, 2018 there were no: (i) disagreements with Fiondella, Milone & LaSaracina LLP (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Fiondella, Milone & LaSaracina LLP, would have caused them to make reference thereto in their report on financial statements for such years; or (ii) reportable events as defined in Item 304(a)(1)(v) of Regulation S-K.
In accordance with Item 304(a)(3) of Regulation S-K, the Company provided Fiondella, Milone & LaSaracina LLP with a copy of this report on Form 8-K prior to its filing with the Securities and Exchange Commission and requested that Fiondella, Milone & LaSaracina LLP furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the above statements and, if it does not agree, the respects in which it does not agree. A copy of the requested letter furnished from Fiondella, Milone & LaSaracina LLP is attached as Exhibit 16.1 to this report.
(b) New independent registered public accounting firm.
On April 23, 2018, and effective the same date, on the recommendation of the Registrant’s Board of Directors, the Registrant engaged RBSM LLP, as its independent registered audit firm to audit the Registrant’s financial statements for the fiscal year ended December 31, 2018 and to perform procedures related to the financial statements included in the Registrant’s quarterly reports on Form 10-Q, beginning with the quarter ending March 31, 2018.
During the fiscal years ended December 31, 2017 and 2016 and through the date of the engagement of RBSM LLP, neither the Registrant nor anyone on its behalf has consulted with RBSM LLP, regarding either:
(1) The application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Registrant's financial statements, and neither was a written report provided to the Registrant nor was oral advice provided that RBSM LLP concluded was an important factor considered by the Registrant in reaching a decision as to an accounting, auditing, or financial reporting issue; or
(2) Any matter that was either the subject of a disagreement or a reportable event, as each term is defined in Items 304(a)(1)(iv) or (v) of Regulation S-K, respectively.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
16.1
Letter of Fiondella, Milone & LaSaracina LLP to the Securities and Exchange Commission dated April 26, 2018.
Two consecutive closes over .02.. Maybe an 8-k tomorrow..